<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530777</url>
  </required_header>
  <id_info>
    <org_study_id>32462-A</org_study_id>
    <secondary_id>07-7306-A01</secondary_id>
    <secondary_id>R03HD057773</secondary_id>
    <nct_id>NCT00530777</nct_id>
  </id_info>
  <brief_title>HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding</brief_title>
  <acronym>VIP</acronym>
  <official_title>HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royalty Research Fund - University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puget Sound Partners for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will determine whether treating pregnant and breastfeeding women
      co-infected with human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2
      (HSV-2) with daily valacyclovir will reduce HIV-1 levels in plasma, genital, and breast milk
      and will decrease the risk of mother-to-child HIV-1 transmission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year over 500,000 children become HIV-1-infected in sub-Saharan Africa after exposure to
      maternal virus in blood, genital secretions, and breast milk. Identifying feasible, safe, and
      affordable interventions that prevent mother-to-child transmission remains a priority for
      HIV-1 prevention research. Interventions to reduce breast milk HIV-1 transmission are lacking
      and most urgently needed.

      We propose a randomized clinical trial to determine whether incorporating HSV-2 suppression
      with valacyclovir into standard prevention of mother-to-child HIV-1 transmission regimens
      will reduce plasma, cervical, and breast milk HIV-1 RNA levels and risk of transmission among
      HIV-1-infected and HSV-2-seropositive women. We plan to enroll a total of 148 HIV-1 and HSV-2
      co-infected pregnant women with CD4&gt;200 cells/μl who seek antenatal care prior to 32 weeks
      gestation at a clinic in Nairobi, Kenya. Women will be randomized to receive either
      valacyclovir suppressive therapy or placebo at 34 weeks gestation and mother-infant pairs
      will be followed for 12 months postpartum. Follow-up visits will be scheduled at 38 weeks
      gestation; birth; 2, 6, 10 and 14 weeks; and 6, 9, and 12 months postpartum. Maternal blood,
      genital, and breast milk specimens obtained at follow-up visits will be used to determine the
      effect of valacyclovir suppressive therapy on plasma and breast milk HIV-1 RNA levels. Infant
      filter paper specimens for HIV-1 DNA assays will be collected at birth; 2, 6, 10 and 14
      weeks; and 6, 9, and 12 months in order to compare the proportion of infants acquiring HIV-1
      by 12 months in the two study arms and determine the timing of HIV-1 infection. In addition,
      we will monitor maternal and infant renal function in preparation for a larger randomized
      clinical trial in Africa. The results of this study will help guide the design of a
      multi-site clinical trial with adequate power to determine the effect of HSV-2 suppression on
      vertical transmission of HIV-1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vertical HIV-1 Transmission</measure>
    <time_frame>1 year postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>HIV Infections</condition>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 seropositive

          -  HSV-2 seropositive

          -  Plans to deliver in Nairobi

          -  Resides and plans to remain in Nairobi for 12 months postpartum

          -  18 years of age or older

          -  CD4 count&gt;250 cells/μl

        Exclusion Criteria:

          -  indication for highly active antiretroviral therapy (e.g., WHO stage III or IV)

          -  hypersensitivity to valacyclovir or acyclovir
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carey Farquhar, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mathare North City Clinic</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, Leroy V, Simonon A, Cartoux M, Combe P, Ouangré A, Ramon R, Ky-Zerbo O, Montcho C, Salamon R, Rouzioux C, Van de Perre P, Mandelbrot L. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Lancet. 1999 Mar 6;353(9155):786-92.</citation>
    <PMID>10459959</PMID>
  </reference>
  <reference>
    <citation>Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, Moulton LH, Ward BJ, Humphrey JH; ZVITAMBO study group. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS. 2005 Apr 29;19(7):699-708.</citation>
    <PMID>15821396</PMID>
  </reference>
  <reference>
    <citation>Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, Wamalwa DC, Lohman-Payne BL, Ashley-Morrow R, Corey L, Farquhar C. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol. 2007 Feb;109(2 Pt 1):403-9. Erratum in: Obstet Gynecol. 2007 Apr;109(4):1002-3.</citation>
    <PMID>17267842</PMID>
  </reference>
  <reference>
    <citation>Chen KT, Segú M, Lumey LH, Kuhn L, Carter RJ, Bulterys M, Abrams EJ; New York City Perinatal AIDS Collaborative Transmission Study (PACTS) Group. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol. 2005 Dec;106(6):1341-8.</citation>
    <PMID>16319261</PMID>
  </reference>
  <reference>
    <citation>Whitehead S, Bollen L, Leelawiwat W, et al. Maternal HSV-2 Cervicovaginal Shedding Increases the Risk of Intra-partum HIV-1 Transmission. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, 2007.</citation>
  </reference>
  <reference>
    <citation>Duffus WA, Mermin J, Bunnell R, Byers RH, Odongo G, Ekwaru P, Downing R. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS. 2005 Nov;16(11):733-5.</citation>
    <PMID>16303067</PMID>
  </reference>
  <reference>
    <citation>Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997 Sep;176(3):766-70.</citation>
    <PMID>9291329</PMID>
  </reference>
  <reference>
    <citation>Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999 Aug 5;341(6):385-93.</citation>
    <PMID>10432323</PMID>
  </reference>
  <reference>
    <citation>Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 5;341(6):394-402.</citation>
    <PMID>10432324</PMID>
  </reference>
  <reference>
    <citation>Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, Parekh B, Mock PA, Bhadrakom C, Chinayon P, Kalish ML, Phillips SK, Granade TC, Subbarao S, Weniger BG, Mastro TD. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 1999 Mar;179(3):590-9.</citation>
    <PMID>9952365</PMID>
  </reference>
  <reference>
    <citation>Chuachoowong R, Shaffer N, Siriwasin W, Chaisilwattana P, Young NL, Mock PA, Chearskul S, Waranawat N, Chaowanachan T, Karon J, Simonds RJ, Mastro TD. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 2000 Jan;181(1):99-106.</citation>
    <PMID>10608756</PMID>
  </reference>
  <reference>
    <citation>Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS. 1998 May 28;12(8):831-7. Review.</citation>
    <PMID>9631135</PMID>
  </reference>
  <reference>
    <citation>Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007 Feb 22;356(8):790-9.</citation>
    <PMID>17314338</PMID>
  </reference>
  <reference>
    <citation>Ozouaki F, Ndjoyi-Mbiguino A, Legoff J, Onas IN, Kendjo E, Si-Mohamed A, Mbopi-Kéou FX, Malkin JE, Bélec L. Genital shedding of herpes simplex virus type 2 in childbearing-aged and pregnant women living in Gabon. Int J STD AIDS. 2006 Feb;17(2):124-7.</citation>
    <PMID>16464276</PMID>
  </reference>
  <reference>
    <citation>Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ; International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS. 2002 Jan;13(1):12-21.</citation>
    <PMID>11802924</PMID>
  </reference>
  <reference>
    <citation>Workowski KA, Berman SM. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2007 Apr 1;44 Suppl 3:S73-6.</citation>
    <PMID>17342670</PMID>
  </reference>
  <reference>
    <citation>Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, Wendel GD Jr. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol. 2006 Jul;108(1):141-7. Erratum in: Obstet Gynecol. 2006 Sep;108(3 Pt 1):695.</citation>
    <PMID>16816068</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol. 2006 Mar;194(3):774-81.</citation>
    <PMID>16522412</PMID>
  </reference>
  <reference>
    <citation>Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, Miller G. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol. 1998 Oct;179(4):846-51.</citation>
    <PMID>9790357</PMID>
  </reference>
  <reference>
    <citation>Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988 Apr;26(4):662-7.</citation>
    <PMID>2835389</PMID>
  </reference>
  <reference>
    <citation>Panteleeff DD, John G, Nduati R, Mbori-Ngacha D, Richardson B, Kreiss J, Overbaugh J. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol. 1999 Feb;37(2):350-3.</citation>
    <PMID>9889216</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>March 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2012</results_first_posted>
  <last_update_submitted>March 22, 2012</last_update_submitted>
  <last_update_submitted_qc>March 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Carey Farquhar</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Disease Transmission, Vertical</keyword>
  <keyword>valacyclovir</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>HIV</keyword>
  <keyword>herpes</keyword>
  <keyword>Herpesvirus 2, Human</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-1 infected pregnant women seeking antenatal care at the Mathare North City Council Clinic in Nairobi Kenya, or referred from neighboring clinics, were recruited for study screening</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Valacyclovir</title>
          <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to adhere to visit schedule</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
          <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.3"/>
                    <measurement group_id="B2" value="26.0" spread="4.5"/>
                    <measurement group_id="B3" value="26.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation</title>
        <time_frame>4 weeks</time_frame>
        <population>Women with paired plasma samples at 34 and 38 weeks gestation</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation</title>
          <population>Women with paired plasma samples at 34 and 38 weeks gestation</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread=".074"/>
                    <measurement group_id="O2" value="0.03" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vertical HIV-1 Transmission</title>
        <time_frame>1 year postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Vertical HIV-1 Transmission</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
          <description>500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>oral placebo twice daily from 34 weeks gestation to 1 year postpartum</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unable to evaluate the effect of valacyclovir on MTCT or on change in HIV-1 RNA among women who were eligible for HAART. Underpowered to detect association between treatment and mother to child HIV transmission.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Carey Farquhar</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-543-4278</phone>
      <email>cfarq@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

